07:00 , Apr 20, 2015 |  BioCentury  |  Finance

Liking Japan's retail exodus

At least one Japanese specialist investor hopes the ongoing rotation out of biotech by the country's retail investors is setting the stage for a new norm marked by a more mature, longer-term investor base and...
07:00 , Apr 6, 2015 |  BioCentury  |  Finance

Up, up and acquired

For the first time since 1Q14, none of the biotech market cap segments fell. While the $200-$499 million tier treaded water, all other segments finished in the black, led by the $1-$4.9 billion segment. Large...
08:00 , Feb 10, 2014 |  BioCentury  |  Finance

A Japanese correction

A Japanese correction Japan's biotechs exhibited the high beta typical of the sector last week, falling more than five times as much as the country's broader markets, which themselves have been taking a beating. Nevertheless, Japanese...
08:00 , Feb 11, 2013 |  BioCentury  |  Finance

Bubbling up in Japan

Japan's biotech stocks have benefited from a spike in interest from retail investors driven in part by last October's Nobel Prize for a Kyoto University stem cell researcher. Company executives who spoke with BioCentury are...
02:28 , Jan 16, 2013 |  BC Extra  |  Company News

OcellO, Merus in cancer antibodies screening deal

OcellO B.V. (Leiden, the Netherlands) partnered with Merus B.V. (Utrecht, the Netherlands) to screen human bispecific antibodies from Merus -- called Biclonics -- for cancer. OcellO will use its 3-D cell culture-based screening technology to...
07:00 , Aug 6, 2012 |  BioCentury  |  Finance

Glint of IPO optimism

Aftermarket performance is better for biotech IPOs this year than it was in 2011. Although the basics of what it takes to get an IPO done haven't changed - deals routinely continue to require a...
08:00 , Jan 2, 2012 |  BioCentury  |  Finance

Living creatively

For small, early stage biotech companies, 2012 could be the year of living creatively. Although public biotechs raised more funds last year than ever before, the vast majority of the money was debt financing by established...
08:00 , Dec 12, 2011 |  BioCentury  |  Finance

Chiome on the range

Chiome on the range Chiome Bioscience Inc. became the fourth Japanese biotech to go public this year - up from a grand total of one in 2010. The antibody play raised ¥507.6 million ($6.5 million) through...
07:00 , Oct 31, 2011 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Affymax Inc. (NASDAQ:AFFY) was up $0.22 to $5.33 last week after saying that FDA's Oncologic Drugs Advisory Committee (ODAC) will meet on Dec. 7 to discuss an NDA for peginesatide to treat anemia in...
00:30 , Oct 25, 2011 |  BC Extra  |  Financial News

3-D Matrix off in trading debut

3-D Matrix Ltd. (JASDAQ:7777) was off Y795 (38%) to Y1,305 in its first day of trading on Monday on the JASDAQ Growth Market of the Osaka Securities Exchange. Last week, the company raised Y1.5 billion...